Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» kidney cancer
kidney cancer
Arcus' new HIF-2a data in kidney cancer hint at potential edge over Merck's Welireg, analysts say
Fierce Biotech
Thu, 10/24/24 - 08:27 pm
Arcus Biosciences
kidney cancer
Merck
casdatifan
Welireg
ArsenalBio raises $325M in one of the year’s largest biotech funding rounds
BioPharma Dive
Wed, 09/4/24 - 11:46 am
Arsenal Bio
funding
biotech
cell therapy
ovarian cancer
kidney cancer
Roche
Bristol Myers Squibb
Aveo spins a silver lining in failed trial of kidney cancer drug Fotivda
Fierce Pharma
Thu, 07/18/24 - 11:06 pm
Aveo Oncology
kidney cancer
Fotivda
Opdivo
Bristol Myers Squibb
ASCO: Merck KGaA, Pfizer's Bavencio combo misses survival mark in crowded kidney cancer space
Fierce Pharma
Thu, 05/23/24 - 09:52 pm
ASCO 2024
Merck KGaA
Bavencio
Pfizer
Inlyta
kidney cancer
clinical tirals
Amid CEO turmoil, Allarity loses rights to Novartis cancer drug over missed payments
Fierce Biotech
Fri, 02/2/24 - 11:57 am
Allarity Therapeutics
Novartis
kidney cancer
ovarian cancer
dovitinib
BMS' subcutaneous Opdivo clears first phase 3 trial
Pharmaphorum
Mon, 01/29/24 - 11:06 am
Bristol Myers Squibb
Opdivo
clinical trials
kidney cancer
subcutaneous Opdivo
ASCO: Merck's Keytruda trips in EGFR lung cancer as Roche's Tecentriq fails in kidney cancer
Fierce Pharma
Tue, 06/6/23 - 04:19 pm
ASCO 2023
Merck
Keytruda
EGFR lung cancer
Roche
Tecentriq
kidney cancer
HistoSonics’ Kidney Cancer Trial Using Non-Invasive Histotripsy Gets FDA Nod
Xtalks
Thu, 02/16/23 - 10:12 am
HistoSonics
FDA
devices
Medtech
histotripsy
kidney cancer
clinical trials
ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?
Fierce Pharma
Mon, 09/12/22 - 10:57 am
ESMO
Roche
Bristol Myers Squibb
kidney cancer
Keytruda
Merck
Opdivo
Yervoy
Exelixis trot out Opdivo-Yervoy-Cabometyx combo win in kidney cancer. Will FDA accept?
Fierce Pharma
Mon, 07/11/22 - 05:48 pm
Exelixis
Cabometyx
kidney cancer
Opdivo
Yervoy
Bristol Myers Squibb
Bristol Myers scraps $2B Nektar partnership after trial failures
BioPharma Dive
Mon, 04/18/22 - 11:42 pm
Bristol Myers Squibb
Nektar Therapeutics
immunotherapy
Opdivo
kidney cancer
bladder cancer
ESMO: Facing new Keytruda combos from Merck, BMS touts 5-year kidney cancer data for Opdivo-Yervoy
Fierce Pharma
Thu, 09/16/21 - 10:56 am
Bristol Myers Squibb
Opdivo
Yervoy
kidney cancer
ESMO
FDA starts speedy review of Keytruda for adjuvant kidney cancer
Pharmaforum
Wed, 08/11/21 - 10:57 am
Merck
FDA
Keytruda
kidney cancer
Go or no go? August FDA decisions for Axsome, Sanofi and Merck
EP Vantage
Fri, 07/30/21 - 11:04 am
FDA
Axsome Therapeutics
Sanofi
Merck
Pompe disease
depression
kidney cancer
Keytruda
ASCO: Merck's Keytruda targets Pfizer's shaky Sutent post-surgery use in kidney cancer
Fierce Pharma
Thu, 06/3/21 - 11:05 pm
ASCO 2021
Merck
Keytruda
kidney cancer
Sutent
Pfizer
Merck's Keytruda, on the heels of a first-line kidney cancer win, targets earlier, post-surgery use
Fierce Pharma
Thu, 04/8/21 - 11:13 am
Merck
Keytruda
renal cell carcinoma
kidney cancer
clinical trials
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer
PM Live
Wed, 02/10/21 - 12:09 am
Bristol Myers Squibb
Exelixix
Opdivo
Cabometyx
kidney cancer
Bristol Myers, Exelixis snag Opdivo-Cabometyx kidney cancer nod to challenge Merck, Pfizer
Fierce Pharma
Mon, 01/25/21 - 11:09 am
Bristol-Myers Squibb
Exelixis
Opdivo
Cabometyx
kidney cancer
FDA
FDA kicks off review of second kidney cancer combo based on BMS’ Opdivo
Pharmaforum
Tue, 10/20/20 - 10:33 am
Bristol-Myers Squibb
Opdivo
kidney cancer
Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer
Yahoo/Zacks.com
Tue, 08/25/20 - 11:19 am
Exelixis
Cabometyx
FDA
kidney cancer
renal cell carcinoma
Bristol-Myers Squibb
Opdivo
Pages
1
2
3
4
5
6
next ›
last »